Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2024 Jun 6:2024:8915166.
doi: 10.1155/2024/8915166. eCollection 2024.

Medication Use Among Pregnant Women With SARS-CoV-2 Infection and Risk of Hospitalization-A Study in Two Brazilian Hospitals

Ricardo Rohweder  1 , Natálya G Pereira  2 , Bruna H Micheletti  2 , Jéssica Mosello  2 , Júlia R M Campos  2 , Matheus G Pereira  2 , Cristina N Santos  2 , Natália L Simões  2 , Regina L B Matielo  2 , Lisandra S Bernardes  2   3 , Maria L R Oppermann  4 , Maria C O Wender  4 , Angela Lupattelli  5 , Hedvig Nordeng  5 , Lavinia Schuler-Faccini  1
Affiliations
Multicenter Study

Medication Use Among Pregnant Women With SARS-CoV-2 Infection and Risk of Hospitalization-A Study in Two Brazilian Hospitals

Ricardo Rohweder et al. J Pregnancy. .

Abstract

There is limited evidence about the use of medications among pregnant women with COVID-19, as well as risk factors for hospitalization due to COVID-19 in pregnancy. We aimed to describe the use of medications among SARS-CoV-2-positive pregnant women at the time around infection and identify predictors for hospitalization due to COVID-19 in two hospitals in Brazil. This is a hospital record-based study among pregnant women with positive SARS-CoV-2 tests between March 2020 and August 2022 from two Brazilian hospitals. Characteristics of sociodemographic, obstetrical, and COVID-19 symptoms were extracted retrospectively. The prevalence use of medications was based on self-reported use, and this was administered at the hospital. Logistic regression was used to estimate predictors of hospitalization due to COVID-19. There were 278 pregnant women included in the study, of which 41 (14.7%) required hospitalization due to COVID-19. The remaining 237 (85.3%) had mild symptoms or were asymptomatic. Most of the women had the infection in the third trimester (n = 149; 53.6%). The most prevalent medications used across all trimesters were analgesics (2.4% to 20.0%), antibacterials (15.0% to 23.1%), and corticosteroids (7.2% to 10.4%). Pre- or gestational hypertensive disorder (odds ratio (OR) 4.94, 95% confidence interval (CI) 1.65, 14.87) and having at least one dose of vaccine against SARS-CoV-2 (OR 0.13, 95% CI 0.04, 0.39) were associated with hospitalization due to COVID-19. Analgesics, antibacterials, and corticosteroids were the most frequently used medications among pregnant women with COVID-19. Women with hypertensive disorders have almost a five-fold increased risk of hospitalization due to COVID-19. Vaccination was the strongest protective factor for severe COVID-19. The COVID-19 vaccination among pregnant women should be promoted, and pregnant women diagnosed with COVID-19 who have hypertensive disorders should be closely monitored.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Flowchart of the process for enrollment, selection, and classification of participants diagnosed with COVID-19 during pregnancy.
See this image and copyright information in PMC

References

    1. Allotey J., Stallings E., Bonet M., et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. The BMJ . 2020;370 doi: 10.1136/bmj.m3320. - DOI - PMC - PubMed
    1. Villar J., Ariff S., Gunier R. B., et al. Maternal and neonatal morbidity and mortality among pregnant women with and without COVID-19 infection: the INTERCOVID multinational cohort study. JAMA Pediatrics . 2021;175(8):817–826. doi: 10.1001/JAMAPEDIATRICS.2021.1050. - DOI - PMC - PubMed
    1. Marchand G., Patil A. S., Masoud A. T., et al. Systematic review and meta-analysis of COVID-19 maternal and neonatal clinical features and pregnancy outcomes up to. AJOG Global Reports . 2022;2(1) doi: 10.1016/J.XAGR.2021.100049. - DOI - PMC - PubMed
    1. Leung C., Simões E., Silva A. C., Oliveira E. A. Are in-hospital COVID-19-related mortality and morbidity in pregnancy associated with gestational age? Ultrasound in Obstetrics & Gynecology: The Official Journal of the International Society of Ultrasound in Obstetrics and Gynecology . 2022;60(2):234–242. doi: 10.1002/uog.24931. - DOI - PMC - PubMed
    1. Guimarães R. M., Reis L. G. C., de Souza Mendes Gomes M. A., Magluta C., de Freitas C. M., Portela M. C. Tracking excess of maternal deaths associated with COVID-19 in Brazil: a nationwide analysis. BMC Pregnancy and Childbirth . 2023;23(1):1–7. doi: 10.1186/S12884-022-05338-Y/FIGURES/2. - DOI - PMC - PubMed

Publication types

Substances

LinkOut - more resources